Technical Reports on Medical Equipment Equities -- Hologic, Wright Medical, Globus Medical, and Edwards Lifesciences

Monday, June 19, 2017 Lifestyle News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 19, 2017 /PRNewswire/ -- has issued research reports on Hologic Inc. (NASDAQ:

HOLX), Wright Medical Group N.V. (NASDAQ: WMGI), Globus Medical Inc. (NYSE: GMED), and Edwards Lifesciences Corp. (NYSE: EW). Medical Appliances and Equipment companies engage in the manufacture of medical instruments, such as dental and surgical appliances.
They also tend to offer below-average dividend yields when compared to the wider market. Learn more about these stocks by downloading their comprehensive and free reports from member's area at:


Marlborough, Massachusetts headquartered Hologic Inc.'s shares finished Friday's session 0.89% lower at $44.32. A total volume of 2.78 million shares was traded, which was above their three months average volume of 2.50 million shares. The stock has gained 3.41% in the last month, 4.06% over the previous three months, and 10.47% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 1.00% and 9.20%, respectively. Moreover, shares of Hologic, which develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the US, Europe, Asia/Pacific, and internationally, have a Relative Strength Index (RSI) of 52.90.

On June 15th, 2017, Hologic announced that the US FDA has granted an expanded clearance for Cynosure's non-invasive body contouring product, SculpSure, to treat the back and inner and outer thighs. The SculpSure treatment is already FDA-cleared for treatment of the abdomen and love handles. HOLX complete research report is just a click away and free at:

Wright Medical 

Shares in Amsterdam, the Netherlands headquartered Wright Medical Group N.V. ended the day 1.28% lower at $26.17. A total volume of 1.63 million shares was traded, which was above their three months average volume of 1.12 million shares. The stock has advanced 13.88% since the start of this year. The Company's shares are trading 0.96% above their 200-day moving average. Moreover, shares of Wright Medical, which designs, manufactures, markets, and sells extremities and biologics products in the US, Europe, Middle-East, Africa, and internationally, have an RSI of 36.40. The complimentary report on WMGI can be downloaded at:

Globus Medical 

Audubon, Pennsylvania headquartered Globus Medical Inc.'s stock rose 0.73%, closing the session at $32.95. A total volume of 691,462 shares was traded, which was above their three months average volume of 582,410 shares. The Company's shares have gained 5.47% in the last one month, 13.15% in the previous three months, and 32.81% on an YTD basis. The stock is trading 6.14% above its 50-day moving average and 25.23% above its 200-day moving average. Additionally, shares of Globus Medical, which focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders, have an RSI of 66.59. Sign up for your complimentary research report on GMED at:

Edwards Lifesciences 

On Friday, shares in Irvine, California headquartered Edwards Lifesciences Corp. finished the session 0.03% higher at $114.99. A total volume of 1.55 million shares was traded, which was above their three months average volume of 1.50 million shares. The stock has gained 2.82% in the last month, 21.81% over the previous three months, and 22.72% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 6.23% and 13.58%, respectively. Moreover, shares of Edwards Lifesciences, which provides products and technologies to treat structural heart disease and critically ill patients worldwide, have an RSI of 61.31.

On June 05th, 2017, Edwards Lifesciences announced that it has received US FDA's approval for aortic and mitral valve-in-valve procedures using the Edwards SAPIEN 3 transcatheter heart valve. The SAPIEN 3 valve is the first transcatheter heart valve approved in the US for the treatment of both aortic and mitral patients, who are at high risk for a subsequent open-heart surgery to replace their bioprosthetic valve. Get free access to your research report on EW at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store